SCHEMBL10189767

SCHEMBL10189767

COc1ccc(-c2[nH]nnc2-c2cc(C)c3c(c2)OCO3)cc1C=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.42
LMNA P02545 4/20 0.41
HPGD P15428 4/20 0.41
ALDH1A1 P00352 4/20 0.36
MAPT P10636 4/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
HTT P42858 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
TNFRSF1A P19438 2/20 0.35
EDNRB P24530 2/20 0.34
EDNRA P25101 2/20 0.34
POLB P06746 1/20 0.34
THRB P10828 1/20 0.34
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
RAF1 P04049 1/20 0.32
BRAF P15056 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10189763 0.85 MAPT (0.40) LMNAHPGDALDH1A1MAPTKDM4E
SCHEMBL10189760 0.85 ALDH1A1 (0.38) LMNAHPGDALDH1A1MAPTKDM4E
SCHEMBL10189768 0.84 MAPT (0.36) LMNAHPGDALDH1A1MAPTKDM4E
SCHEMBL15158945 0.84 MAPT (0.38) ERN1LMNAHPGDALDH1A1MAPT
SCHEMBL10189762 0.81 MAPT (0.39) LMNAHPGDALDH1A1MAPTKDM4E
SCHEMBL10189743 0.81 LMNA (0.47) ERN1LMNAALDH1A1MAPTRAF1
SCHEMBL10189761 0.81 ALDH1A1 (0.34) LMNAHPGDALDH1A1MAPTKDM4E
SCHEMBL10189764 0.78 KIT (0.37) LMNAHPGDALDH1A1MAPTKDM4E
SCHEMBL10189779 0.77 MAPK1 (0.34) LMNAHPGDALDH1A1MAPTKDM4E
SCHEMBL3308523 0.77 ALDH1A1 (0.46) LMNAHPGDALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 ERN1 3240/4885LMNA 2274/4885HPGD 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.